Patricia Inácio, PhD,  science writer—

Adults and children with cystic fibrosis (CF) experienced a marked increase in food insecurity — meaning a limited or uncertain availability of foods that are nutritionally adequate and safe  — during the COVID-19 pandemic, a U.S. study found. Patients with food insecurity also reported poorer mental health and self-care…

Exon skipping may be a promising approach for cystic fibrosis (CF) patients carrying nonsense mutations in the CFTR gene, which render current CF therapies less effective, a study reported. Researchers were able to raise CFTR protein function and protein response to approved CF therapies in cells isolated from a patient…

In contrast to vitamins A and E, the early and sustained use of supplements of vitamin D in young children with cystic fibrosis (CF) led to later and variable responses, a study found. Nearly one-fifth (17%) of these children continued to have low vitamin D levels at age…

Note: This story has been updated to clarify that the Cystic Fibrosis Foundation has funded more than $100 million in various studies through its Infection Research Initiative, not that it has raised funding for future research.  The Cystic Fibrosis Foundation (CFF) has funded more than $100 million in various studies to…

Infection with the environmental bacteria Achromobacter in children with cystic fibrosis (CF) is linked with poorer lung function and more pulmonary exacerbations, a study suggests. These findings highlight the need to identify Achromobacter infection promptly so that children can receive appropriate treatment.  “Our results may indicate that…

Peptilogics has won an award to conduct research for two antibacterial peptides as a first-line therapy to fight antibiotic-resistant bacteria in the lungs of people with cystic fibrosis (CF). According to a press release, the award, by the Cystic Fibrosis Foundation, will support further preclinical research of…

Cystic Fibrosis News Today brought you daily coverage of the latest scientific findings, treatment developments, and clinical trials related to cystic fibrosis (CF) throughout 2021, a year still marked by the COVID-19 pandemic. We look forward to reporting more news to patients, family members, and caregivers dealing with CF during 2022.

Elexacaftor (VX-445), a next-generation CFTR corrector that is part of the triple-combination therapy Trikafta, is also a potentiator, a study reports. Results further showed that in combination with ivacaftor, sold as Kalydeco and also a potentiator, elexacaftor boosts ion flow across CFTR, the…

Health Canada has granted priority review to Vertex Pharmaceuticals’ application seeking the approval of Kalydeco (ivacaftor) to treat cystic fibrosis (CF) patients, ages 4 months to 18 years, carrying the R117H mutation in the CFTR gene. The intended label extension is for patients who weigh at least 5 kilograms…

A non-invasive ultrasound imaging technique may be able to detect changes in the pancreas of children with cystic fibrosis (CF) and aid in an early diagnosis of exocrine pancreatic insufficiency, or EPI — which occurs when the pancreas doesn’t make enough digestive enzymes — a Turkish study suggests.